B. Sherman

676 total citations
16 papers, 525 citations indexed

About

B. Sherman is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, B. Sherman has authored 16 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 7 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in B. Sherman's work include PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and Advanced Breast Cancer Therapies (4 papers). B. Sherman is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and Advanced Breast Cancer Therapies (4 papers). B. Sherman collaborates with scholars based in United States. B. Sherman's co-authors include C. Rocha, C. R. Bradley, Valeria Ossovskaya, R E Kerber, John Pippen, Debra A. Patt, Joyce O’Shaughnessy, Cynthia R. Osborne, Joyce O’Shaughnessy and Шломо Мелмед and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and American Journal of Clinical Nutrition.

In The Last Decade

B. Sherman

16 papers receiving 491 citations

Peers

B. Sherman

ONCOL

MB

CR

PRM

GENET

Pia Alhopuro Finland

Nilüfer Güler Türkiye

María Roqué Argentina

Kimihiro Tanaka Japan

Francesca Garbini Italy

Aurélie Catteau France

Jung Hun Song South Korea

Vincent A. DiPippo United States

Eleanor Latta Canada

Melania E. Mercado-Pimentel United States

Pia Alhopuro Finland

B. Sherman

469 ×1.5

ONCOL

438 ×2.5

MB

200 ×1.3

CR

72 ×0.8

PRM

91 ×1.1

GENET

Citations per year, relative to B. Sherman B. Sherman (= 1×) peers Pia Alhopuro

Countries citing papers authored by B. Sherman

Since Specialization

Citations

This map shows the geographic impact of B. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Sherman more than expected).

Fields of papers citing papers by B. Sherman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Sherman. The network helps show where B. Sherman may publish in the future.

Co-authorship network of co-authors of B. Sherman

This figure shows the co-authorship network connecting the top 25 collaborators of B. Sherman. A scholar is included among the top collaborators of B. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Sherman. B. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Solnik, M. Jonathon, Jennifer T. Anger, Renaldo C. Blocker, et al.. (2013). The Additive Effect of Flow Disruptions in Robotic-Assisted Pelvic Surgery. Journal of Minimally Invasive Gynecology. 20(6). S31–S32. 1 indexed citations

2.

Flaherty, Patrick, Irene Wapnir, Bruce L. Daniel, et al.. (2011). P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.. Cancer Research. 71(24_Supplement). P3–14. 2 indexed citations

3.

O’Shaughnessy, Joyce, JL Blum, C. Rocha, et al.. (2009). Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.. Cancer Research. 69(2_Supplement). 2120–2120. 11 indexed citations

4.

O’Shaughnessy, Joyce, Cynthia R. Osborne, John Pippen, et al.. (2009). G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. European Journal of Cancer Supplements. 7(3). 7–7. 9 indexed citations

5.

O’Shaughnessy, Joyce, John Pippen, Debra A. Patt, et al.. (2009). Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. Journal of Clinical Oncology. 27(18S). 3–3. 34 indexed citations

6.

O’Shaughnessy, Joyce, John Pippen, Debra A. Patt, et al.. (2009). Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. Journal of Clinical Oncology. 27(18_suppl). 3–3. 73 indexed citations

7.

O’Shaughnessy, Joyce, John Pippen, Debra A. Patt, et al.. (2009). Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).. Cancer Research. 69(24_Supplement). 3122–3122. 35 indexed citations

8.

O’Shaughnessy, Joyce, Cynthia R. Osborne, John Pippen, et al.. (2009). Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. Journal of Clinical Oncology. 27(15_suppl). 3–3. 195 indexed citations

9.

Ossovskaya, Valeria, et al.. (2007). P57 The PARP1 gene is over-expressed in triple negative breast cancer. European Journal of Cancer Supplements. 5(8). 31–31. 1 indexed citations

10.

Sherman, B., et al.. (1999). Atropine sulfate--a current review of a useful agent for controlling salivation during dental procedures.. PubMed. 47(1). 56–60; quiz 62. 5 indexed citations

11.

Smith, Richard, et al.. (1993). Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle & Nerve. 16(6). 624–633. 53 indexed citations

12.

Johanson, A, José Cara, James W. Frane, et al.. (1990). Response to growth hormone in children with idiopathic short stature. 79(366). 24–26. 11 indexed citations

13.

Hintz, Raymond L., et al.. (1988). Treatment of Turner's Syndrome with Recombinant Human Growth Hormone (Somatrem). Acta Paediatrica. 77(s343). 47–52. 7 indexed citations

14.

Hintz, Raymond L., et al.. (1988). 29 PRETREATMENT, IGF-I CORRELATES WITH GROWTH RESPONSE TO GH IN HYPOPITUITARISM: THE IMPORTANCE OF ACID SEPARATION. Pediatric Research. 24(4). 522–522. 2 indexed citations

15.

Sherman, B., et al.. (1975). Evaluation of amino acid infusions as protein-sparing agents in normal adult subjects. American Journal of Clinical Nutrition. 28(5). 477–481. 16 indexed citations

16.

Kerber, R E & B. Sherman. (1975). Echocardiographic evaluation of pericardial effusion in myxedema. Incidence and biochemical and clinical correlations.. Circulation. 52(5). 823–827. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact